ABUS
Price
$3.84
Change
-$0.01 (-0.26%)
Updated
Oct 4 closing price
31 days until earnings call
ORMP
Price
$2.35
Change
-$0.06 (-2.49%)
Updated
Oct 4 closing price
34 days until earnings call
Ad is loading...

ABUS vs ORMP

Header iconABUS vs ORMP Comparison
Open Charts ABUS vs ORMPBanner chart's image
Arbutus Biopharma
Price$3.84
Change-$0.01 (-0.26%)
Volume$636.89K
CapitalizationN/A
Oramed Pharmaceuticals
Price$2.35
Change-$0.06 (-2.49%)
Volume$77.57K
CapitalizationN/A
View a ticker or compare two or three
ABUS vs ORMP Comparison Chart
Loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ABUS vs. ORMP commentary
Oct 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a StrongSell and ORMP is a StrongSell.

COMPARISON
Comparison
Oct 06, 2024
Stock price -- (ABUS: $3.84 vs. ORMP: $2.35)
Brand notoriety: ABUS and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 52% vs. ORMP: 72%
Market capitalization -- ABUS: $723.04M vs. ORMP: $99.48M
ABUS [@Biotechnology] is valued at $723.04M. ORMP’s [@Biotechnology] market capitalization is $99.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ABUS is a better buy in the long-term than ORMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 3 TA indicator(s) are bullish while ORMP’s TA Score has 4 bullish TA indicator(s).

  • ABUS’s TA Score: 3 bullish, 7 bearish.
  • ORMP’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ORMP is a better buy in the short-term than ABUS.

Price Growth

ABUS (@Biotechnology) experienced а +0.26% price change this week, while ORMP (@Biotechnology) price change was -5.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.46%. For the same industry, the average monthly price growth was +1.89%, and the average quarterly price growth was -5.77%.

Reported Earning Dates

ABUS is expected to report earnings on Nov 06, 2024.

ORMP is expected to report earnings on Nov 08, 2024.

Industries' Descriptions

@Biotechnology (+1.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABUS($723M) has a higher market cap than ORMP($99.5M). ABUS YTD gains are higher at: 53.600 vs. ORMP (1.732). ORMP has higher annual earnings (EBITDA): 25.5M vs. ABUS (-75.48M). ORMP has more cash in the bank: 153M vs. ABUS (142M). ORMP has less debt than ABUS: ORMP (486K) vs ABUS (1.6M). ABUS has higher revenues than ORMP: ABUS (10.1M) vs ORMP (0).
ABUSORMPABUS / ORMP
Capitalization723M99.5M727%
EBITDA-75.48M25.5M-296%
Gain YTD53.6001.7323,095%
P/E RatioN/A4.78-
Revenue10.1M0-
Total Cash142M153M93%
Total Debt1.6M486K329%
FUNDAMENTALS RATINGS
ABUS vs ORMP: Fundamental Ratings
ABUS
ORMP
OUTLOOK RATING
1..100
668
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
55100
SMR RATING
1..100
9754
PRICE GROWTH RATING
1..100
4160
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (54) in the Pharmaceuticals Other industry is in the same range as ABUS (64) in the Biotechnology industry. This means that ORMP’s stock grew similarly to ABUS’s over the last 12 months.

ABUS's Profit vs Risk Rating (55) in the Biotechnology industry is somewhat better than the same rating for ORMP (100) in the Pharmaceuticals Other industry. This means that ABUS’s stock grew somewhat faster than ORMP’s over the last 12 months.

ORMP's SMR Rating (54) in the Pharmaceuticals Other industry is somewhat better than the same rating for ABUS (97) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than ABUS’s over the last 12 months.

ABUS's Price Growth Rating (41) in the Biotechnology industry is in the same range as ORMP (60) in the Pharmaceuticals Other industry. This means that ABUS’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (99) in the Pharmaceuticals Other industry is in the same range as ABUS (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to ABUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSORMP
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 17 days ago
80%
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REEMF0.480.04
+9.46%
Rare Element Resources Ltd.
AHCHY15.980.76
+5.02%
Anhui Conch Cement Co., Ltd.
JAPSY8.280.07
+0.85%
Japan Airlines Ltd
ADYYF1473.0010.00
+0.68%
Adyen N.V.
VLTLF0.33N/A
-0.75%
VOLT LITHIUM CORP.

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with ROIV. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
-0.26%
ROIV - ABUS
44%
Loosely correlated
+1.52%
ARRY - ABUS
43%
Loosely correlated
+2.06%
AXON - ABUS
42%
Loosely correlated
+1.63%
LRMR - ABUS
40%
Loosely correlated
+1.99%
INZY - ABUS
39%
Loosely correlated
+2.17%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with KRYS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-2.49%
KRYS - ORMP
48%
Loosely correlated
+0.67%
ALDX - ORMP
45%
Loosely correlated
+2.20%
BPMC - ORMP
44%
Loosely correlated
+0.58%
BTAI - ORMP
44%
Loosely correlated
+6.31%
INO - ORMP
44%
Loosely correlated
-1.77%
More